newsfilter
← Earnings
Earnings Releases·

Vivani Medical — Third Quarter 2026 Earnings Summary

  • Cash and equivalents decreased to $15.5 million as of September 30, 2026, from $20.8 million in June 2026; net loss for the quarter was $7.3 million versus $6.5 million in the prior year period, with total operating expenses rising 3% year-over-year to $21.4 million for the nine-month period.
  • Top-line results for the SLIM-1 Phase 1 trial of NPM-139 are expected in November 2026, with an Investigational New Drug Application for a Phase 2 study planned for 2027.
  • The transition of Cortigent into an independent, publicly traded company is anticipated shortly following final regulatory approval, concurrent with ClearOne pursuing $10 million to $15 million in financing.
  • Vivani remains a clinical-stage company with no outstanding revenue, relying on its proprietary NanoPortal™ technology to differentiate NPM-139 in the GLP-1 market through a reversible delivery mechanism.
Company
VIVANI MEDICAL INC
Sector
Healthcare
Industry
Biotechnology